A roundup of some skin cancer news and updates that occurred in 2020 that patients may have missed.
There were several updates in the field of skin cancer in 2020. Here, CURE® looks back at some of the most-read news and updates in the field of skin cancer that patients may have missed.
Patients with stage 3 melanoma who had one or more circulating tumor cells were found to relapse sooner, providing physicians with an important biomarker to treat the likelihood of relapse. READ MORE.
Adjuvant Tafinlar (dabrafenib) and Mekinist (trametinib) elicited a greater than 50% relapse-free survival (RFS) rate in patients with resected, stage 3 BRAF V600E/K-mutant melanoma, according to findings from a five-year analysis of the phase 3 COMBI-AD trial. READ MORE.
A personalized vaccine has demonstrated long-term disease-free and overall survival benefits in patients with stage 3 or stage 4 melanoma at a high risk of recurrence following complete surgical resection, according to the vaccine’s manufacturer, Elios Therapeutics. READ MORE.
Patients appear open to the idea of using artificial intelligence (AI) to help in screening for skin cancer, however many patients stress the need to preserve the patient-physician relationship if implemented, according to study results published in JAMA Dermatology. READ MORE.
Following a median follow-up of three years, the use of immunotherapy agent Keytruda (pembrolizumab) for the adjuvant treatment of patients with resected, high-risk, stage 3 melanoma demonstrated a sustained and clinical meaningful improvement in recurrence-free survival (RFS), compared with placebo. READ MORE.
